| Cohort1 (N=81) |
Cohort2 (N=52) |
Cohort3 (N=102) |
Tongji (N=59) |
P-value | |
|---|---|---|---|---|---|
| Sex | |||||
| Female | 6 (7.4%) | 7 (13.5%) | 0 (0%) | 13 (22.0%) | NA |
| Male | 75 (92.6%) | 45 (86.5%) | 0 (0%) | 46 (78.0%) | |
| Missing | 0 (0%) | 0 (0%) | 102 (100%) | 0 (0%) | |
| Age (years) | |||||
| Mean (SD) | 63.2 (11.5) | 63.0 (6.85) | 63.0 (9.31) | 61.2 (8.28) | 0.812 |
| Median [Min, Max] | 66.0 [2.00, 80.0] | 63.0 [49.0, 76.0] | 63.5 [35.0, 84.0] | 62.0 [37.0, 77.0] | |
| Smoking_history | |||||
| 0 | 19 (23.5%) | 12 (23.1%) | 13 (12.7%) | 26 (44.1%) | <0.001 |
| 1 | 55 (67.9%) | 36 (69.2%) | 89 (87.3%) | 33 (55.9%) | |
| Missing | 7 (8.6%) | 4 (7.7%) | 0 (0%) | 0 (0%) | |
| Stage | |||||
| III | 7 (8.6%) | 3 (5.8%) | 23 (22.5%) | 8 (13.6%) | 0.0196 |
| IV | 74 (91.4%) | 49 (94.2%) | 79 (77.5%) | 50 (84.7%) | |
| IV | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.7%) | |
| 治疗线数 | |||||
| 1 | 75 (92.6%) | 48 (92.3%) | 101 (99.0%) | 0 (0%) | NA |
| 2 | 6 (7.4%) | 4 (7.7%) | 1 (1.0%) | 0 (0%) | |
| Missing | 0 (0%) | 0 (0%) | 0 (0%) | 59 (100%) | |
| Best_response | |||||
| CR | 0 (0%) | 0 (0%) | 1 (1.0%) | 0 (0%) | 0.00913 |
| PD | 2 (2.5%) | 0 (0%) | 0 (0%) | 7 (11.9%) | |
| PD | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.7%) | |
| PR | 38 (46.9%) | 22 (42.3%) | 49 (48.0%) | 27 (45.8%) | |
| PR | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.7%) | |
| SD | 21 (25.9%) | 22 (42.3%) | 51 (50.0%) | 23 (39.0%) | |
| Missing | 20 (24.7%) | 8 (15.4%) | 1 (1.0%) | 0 (0%) | |
| Clinical_benefit | |||||
| DCB | 65 (80.2%) | 43 (82.7%) | 99 (97.1%) | 31 (52.5%) | <0.001 |
| NDB | 15 (18.5%) | 9 (17.3%) | 2 (2.0%) | 15 (25.4%) | |
| Missing | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 13 (22.0%) |